This case study describes how a global evidence-generation enterprise supporting 400,000+ patients across 80 countries improved predictability and cost-effectiveness of its clinical-trial product delivery by adopting a SAFe-based delivery model and stronger automation. Facing planning and execution gaps that caused timeline slips, occasional missed commitments, and higher operating costs, the company partnered with Brillio, which rapidly staffed an 80+ person team, ran workshops with product management, and defined a holistic delivery strategy combining process changes, technical implementations, and tool integrations. Brillio strengthened estimation, planning, and risk management, formed dedicated DevOps and test automation teams, and ensured compliance and release documentation aligned t

Join for free to read